keyword
MENU ▼
Read by QxMD icon Read
search

therapeutic patent

keyword
https://www.readbyqxmd.com/read/28530148/an-industry-update-what-is-new-in-the-field-of-therapeutic-delivery-this-month
#1
Elaine Harris
The present industry update covers the period 1-28 February 2017. Information was sourced primarily from company press releases, regulatory and patent agencies, scientific literature and various news websites. A report issued this month indicated that the recent American election has influenced the rate and volume of pharma acquisitions and mergers (A&M) in the final quarter of 2016 and it remains to be seen what (if any) is the effect on the therapeutic drug delivery sector in the longer term. There was positive approval news this month for Valeant, Intellipharmaceutics and Pfizer for products that offered novel therapeutic delivery...
June 2017: Therapeutic Delivery
https://www.readbyqxmd.com/read/28525469/safety-and-efficacy-study-of-an-ozone-laser-combined-therapy-using-puncture-needle-in-the-treatment-of-patients-with-cervical-spondylosis
#2
Ke Gu, Yuqiu Yan, Wu Wei, Yan Li, Wenli Liu, Yang Guo, Long Yu
STUDY DESIGN AND METHODS: Fifty-eight patients with cervical spondylosis (CS) were treated with patented technology of ozone laser combined therapy using puncture needle between August 2008 and February 2010. Visual Analogue Scale (VAS) score changes before and 6 months after surgery and MacNab score criteria 6 months after surgery were analyzed. BACKGROUND AND OBJECTIVE: CS normally occurs over the age of 50 and broadly presents as either myelopathy or radiculopathy...
June 2017: Clinical Spine Surgery
https://www.readbyqxmd.com/read/28521529/potential-of-novel-drug-delivery-systems-in-the-management-of-topical-candidiasis
#3
Mahima Mathur, Kusum Devi Vemula
High prevalence of topical fungal infections is perceived in majority of nations worldwide accounting for numerous serious systemic complications. Of several fungal infections, candidiasis is one of the widespread infections which is manifested due to localization and proliferation of fungi. Present pharmacotherapy offers an effective treatment but possesses serious limitations like inadequate solubility, ineffectiveness in lowering diseased condition and patient incompliance. Several attempts to overcome these shortcomings and building suitable technology platforms for development of appropriate dosage forms which can enhance effectiveness, patient acceptability while maintaining safety, efficacy and affordability of drug delivery, have been made...
May 18, 2017: Journal of Drug Targeting
https://www.readbyqxmd.com/read/28510271/application-of-combination-high-throughput-phenotypic-screening-and-target-identification-methods-for-the-discovery-of-natural-product-based-combination-drugs
#4
REVIEW
Monica Isgut, Mukkavilli Rao, Chunhua Yang, Vangala Subrahmanyam, Padmashree C G Rida, Ritu Aneja
Modern drug discovery efforts have had mediocre success rates with increasing developmental costs, and this has encouraged pharmaceutical scientists to seek innovative approaches. Recently with the rise of the fields of systems biology and metabolomics, network pharmacology (NP) has begun to emerge as a new paradigm in drug discovery, with a focus on multiple targets and drug combinations for treating disease. Studies on the benefits of drug combinations lay the groundwork for a renewed focus on natural products in drug discovery...
May 16, 2017: Medicinal Research Reviews
https://www.readbyqxmd.com/read/28503962/impact-of-price-deregulation-policy-on-the-affordability-of-essential-medicines-for-women-s-health-a-panel-data-analysis
#5
Junjie Liu, Liming Wang, Chenxi Liu, Xinping Zhang
BACKGROUND: A new policy which required deregulation on prices of off-patent medicines for women's health during procurement was introduced in China in September 2015. The current study examines this policy's impact on the affordability of essential medicines for women's health. METHODS: Based on product-level panel data, a fixed effect regression model is employed by using procurement records from Hubei Centralist Tender for Drug Purchase platform. In the model, Affordability was measured with prices...
May 15, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28503221/management-of-musculoskeletal-pain-in-retail-drug-outlets-within-a-nigerian-community-a-descriptive-study
#6
Samirah N Abdu-Aguye, Aishatu Shehu, Ubaidullah I Ahmad
OBJECTIVE: This work aimed to describe attitudes and practices of both community pharmacies and patent and proprietary medicine vendor (PPMV) outlets towards over-the-counter (OTC) analgesic use for musculoskeletal pain states within Zaria, Nigeria. METHODS: The study was carried out in 2 phases from May to August 2016. Phase one was a cross-sectional survey of 40 retail drug outlets (10 community pharmacies and 30 PPMVs). A simulated patient scenario of a young adult male complaining of acute onset back pain was used to collect data on the type and quality of analgesic recommended, duration of consultation, as well as nature of information provided during the drug dispensing process...
January 2017: Pharmacy Practice
https://www.readbyqxmd.com/read/28501916/micrornas-in-injury-and-repair
#7
REVIEW
Cory V Gerlach, Vishal S Vaidya
Organ damage and resulting pathologies often involve multiple deregulated pathways. MicroRNAs (miRNAs) are short, non-coding RNAs that regulate a multitude of genes at the post-transcriptional level. Since their discovery over two decades ago, miRNAs have been established as key players in the molecular mechanisms of mammalian biology including the maintenance of normal homeostasis and the regulation of disease pathogenesis. In recent years, there has been substantial progress in innovative techniques to measure miRNAs along with advances in targeted delivery of agents modulating their expression...
May 13, 2017: Archives of Toxicology
https://www.readbyqxmd.com/read/28485666/are-therapeutic-antibodies-still-patentable-at-the-european-patent-office
#8
Vicki Allen, Graham Matthew Lewis
No abstract text is available yet for this article.
May 9, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28482791/3d-qsar-comfa-comsia-and-molecular-docking-studies-on-histone-deacetylase-1-selective-inhibitors
#9
Tooba Abdizadeh, Razieh Ghodsi, Farzin Hadizadeh
BACKGROUND: Histone deacetylases (HDACs) are attractive therapeutic targets for the treatment of cancer and other diseases. There are numerous published patent applications till 2017. It was claimed that novel HDACIs were optimized as potential drug candidates, designed for regional or systemic release, and created as significant inhibitors. OBJECTIVE: In the present study, 3D-QSAR and molecular docking were used to provide a theoretical basis for finding highly potent anti-tumor drugs...
May 8, 2017: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/28482702/an-introduction-to-biosimilar-cancer-therapeutics-definitions-rationale-for-development-and-regulatory-requirements
#10
Christian Buske, Michinori Ogura, Hyuk-Chan Kwon, Sang Wook Yoon
Monoclonal antibodies and other biologic drugs play important roles in the treatment of various hematological malignancies and solid tumors. However, such drugs are intrinsically more expensive to develop than small molecules and their clinical benefits are often accompanied by challenges relating to affordability and access. Patent expiry for 'originator' biologics is providing opportunities for a new generation of biosimilar drugs, potentially capable of relieving pressure on healthcare budgets. This article discusses key characteristics of biosimilars, distinguishes them from generics and noncomparable biologics and outlines the robust regulatory requirements that must be followed to establish biosimilarity with a reference product...
May 2017: Future Oncology
https://www.readbyqxmd.com/read/28482700/clinical-development-of-ct-p10-and-other-biosimilar-cancer-therapeutics
#11
Won Seog Kim, Bertrand Coiffier, Hyuk-Chan Kwon, SuYeon Kim
Biosimilars are highly similar versions of approved biologic drugs that may confer equivalent efficacy at a reduced cost. Patents for several biological cancer therapeutics are past or approaching expiry, presenting an opportunity to increase affordability and global accessibility of key drugs through the development of biosimilars. To receive approval, a biosimilar must show no clinically meaningful differences from the reference product in terms of efficacy or safety. The first monoclonal antibody biosimilar cancer therapeutic to gain approval was CT-P10, a biosimilar of rituximab...
May 2017: Future Oncology
https://www.readbyqxmd.com/read/28481238/the-adenosinergic-system-as-a-therapeutic-target-in-the-vasculature-new-ligands-and-challenges
#12
REVIEW
Joana Beatriz Sousa, Carmen Diniz
Adenosine is an adenine base purine with actions as a modulator of neurotransmission, smooth muscle contraction, and immune response in several systems of the human body, including the cardiovascular system. In the vasculature, four P1-receptors or adenosine receptors-A₁, A2A, A2B and A₃-have been identified. Adenosine receptors are membrane G-protein receptors that trigger their actions through several signaling pathways and present differential affinity requirements. Adenosine is an endogenous ligand whose extracellular levels can reach concentrations high enough to activate the adenosine receptors...
May 6, 2017: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/28480833/nanoemulsion-for-the-effective-treatment-and-management-of-anti-tubercular-drug-therapy
#13
Sarwar Beg, Sumant Saini, Sarim Imam, Mahfoozur Rahman, Suryakanta Swain, M S Hasnain
BACKGROUND: Tuberculosis is considered as one of the deadliest diseases of human existence. Since ancient age the treatment of tuberculosis has been highly challenging primarily owing to the pathogenic nature of the Mycobacterium and its diverse spots of localization in human body including lungs, liver, spleen, eye, meninges and lymph nodes. METHODS: The conventional drug therapy employed for the treatment of tuberculosis is not highly satisfactorily owing to low oral bioavailability of the drugs...
May 3, 2017: Recent Patents on Anti-infective Drug Discovery
https://www.readbyqxmd.com/read/28479860/rituximab-in-the-treatment-of-follicular-lymphoma-the-future-of-biosimilars-in-the-evolving-therapeutic-landscape
#14
REVIEW
Janakiraman Subramanian, Jamie Cavenagh, Bhardwaj Desai, Ira Jacobs
Follicular lymphoma (FL) is the second most common type of non-Hodgkin's lymphoma. FL is an incurable disease with treatment options ranging from a "watch-and-wait" approach to localized therapy with radiation or systemic therapy with rituximab in combination with chemotherapy regimens. This review summarizes the role of rituximab across the spectrum of FL treatment and the evolving therapeutic landscape with the emergence of novel agents currently in clinical development. Despite the prospect of new agents on the horizon, it is widely accepted that rituximab will remain as the cornerstone of therapy because of its established long-term efficacy...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28476677/ethnobotanical-study-of-medicinal-plants-used-by-ribeirinhos-in-the-north-araguaia-microregion-mato-grosso-brazil
#15
Reginaldo Vicente Ribeiro, Isanete Geraldini Costa Bieski, Sikiru Olaitan Balogun, Domingos Tabajara de Oliveira Martins
ETHNOPHARMACOLOGICAL IMPORTANCE: Currently, in many traditional communities, such as the riverine community in the North Araguaia microregion (Mato Grosso, Brazil), plant knowledge and use represent the main, if not the only, therapeutic resource for the maintenance of health and/or treatment of diseases. This study aimed to identify and document species of medicinal plants used by local experts from riverine communities in the North Araguaia microregion in Mato Grosso State, and to further chemical and pharmacological studies on species selected based on searches in the relevant literature...
May 2, 2017: Journal of Ethnopharmacology
https://www.readbyqxmd.com/read/28460551/cancer-stem-cell-csc-inhibitors-a-review-of-recent-patents-2012-2015
#16
Prashant S Kharkar
Cancer stem cells (CSCs) mediate tumor initiation and maintenance. These cells are chemoresistant and possess characteristics such as self-renewal, pluripotency, plasticity and differentiation. They have aberrant or altered signaling pathways depending on tumor microenvironment, tumor type, etc. CSCs are responsible for highly aggressive and invasive form of the disease following chemo- and/or radiotherapy. Eliminating CSCs is likely to improve the survival rate in patients. Several anti-CSC strategies and associated targets have been proposed and validated till date...
May 5, 2017: Expert Opinion on Therapeutic Patents
https://www.readbyqxmd.com/read/28460441/inflammatory-breast-cancer-tumor-emboli-express-high-levels-of-anti-apoptotic-proteins-use-of-a-quantitative-high-content-and-high-throughput-3d-ibc-spheroid-assay-to-identify-targeting-strategies
#17
Jay Arora, Scott J Sauer, Michael Tarpley, Peter Vermeulen, Charlotte Rypens, Steven Van Laere, Kevin P Williams, Gayathri R Devi, Mark W Dewhirst
Inflammatory breast cancer (IBC) is one of the most lethal breast cancer variants; with existing therapy, 5-yr survival rate is only 35%. Current barriers to successful treatment of IBC include frequent infiltration and the presence of tumor cell clusters, termed tumor emboli, within the breast parenchyma and lymphatics. Prior studies have identified the role of anti-apoptotic signaling, in particular hyperactivation of NFκB and its target genes, in IBC pathobiology and therapeutic resistance. The objectives of this study were to: (1) determine if IBC tumor emboli express anti-apoptotic proteins and (2) develop a high content, multiparametric assay to assess the morphology of the IBC 3D spheroids and to optimize a high throughput format to screen for compounds that can inhibit the formation of the IBC tumor clusters/embolic structures...
April 18, 2017: Oncotarget
https://www.readbyqxmd.com/read/28457114/anti-blys-treatment-of-36-israeli-systemic-lupus-erythematosus-patients
#18
Zev Sthoeger, Margalit Lorber, Yuval Tal, Elias Toubi, Howard Amital, Shaye Kivity, Pnina Langevitz, Ilan Asher, Daniel Elbirt, Nancy Agmon Levin
BACKGROUND: Anti-BLyS treatment with the human belimumab monoclonal antibody was shown to be a safe and effective therapeutic modality in lupus patients with active disease (i.e., without significant neurological/renal involvement) despite standard treatment. OBJECTIVES: To evaluate the "real-life" safety and efficacy of belimumab added to standard therapy in patents with active lupus in five Israeli medical centers. METHODS: We conducted a retrospective open-labeled study of 36 lupus patients who received belimumab monthly for at least 1 year in addition to standard treatment...
January 2017: Israel Medical Association Journal: IMAJ
https://www.readbyqxmd.com/read/28445377/first-lower-two-thirds-osteomyocutaneous-facial-allograft-perfused-by-a-unilateral-facial-artery-outcomes-and-vascularization-at-1-year-after-transplantation
#19
Sebastian Fischer, Thomas C Lee, Nicco Krezdorn, Muayyad Alhefzi, Maximilian Kueckelhaus, Ericka M Bueno, Bohdan Pomahac
BACKGROUND: Facial allotransplantation provides a unique opportunity to restore facial form and function in severely disfigured patients. Using a single unilateral facial artery for vascularization can significantly reduce surgical duration and thus facilitate the practice of face transplantation. METHODS: A 33-year-old man with a history of high-energy ballistic trauma received a facial allograft comprising the lower two-thirds of the face, including maxilla and mandible...
May 2017: Plastic and Reconstructive Surgery
https://www.readbyqxmd.com/read/28434477/niuhuang-jiangya-preparation-a-traditional-chinese-patent-medicine-for-essential-hypertension-a-systematic-review
#20
REVIEW
Hui Wang, Chunxiang Liu, Jingbo Zhai, Hongcai Shang
OBJECTIVES: Niuhuang Jiangya Preparation (NHJYP) is one of the most commonly used traditional Chinese patent medicines for essential hypertension (EH) in China. Our meta-analysis performed a systematic evaluation on the therapeutic efficacy and safety of NHJYP for EH. DESIGN: Systematic review and meta-analysis. METHODS: PubMed, Embase, the Cochrane library, CNKI,VIP, Sinomed, and Wanfang Database were searched up to June 2015. Randomized controlled trials (RCTs) comparing NHJYP or combined with western antihypertensive drugs (WAD) versus WAD were included...
April 2017: Complementary Therapies in Medicine
keyword
keyword
55120
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"